Compare ENVX & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVX | ORKA |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | ENVX | ORKA |
|---|---|---|
| Price | $5.87 | $32.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $17.14 | ★ $52.70 |
| AVG Volume (30 Days) | ★ 7.1M | 454.9K |
| Earning Date | 02-25-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,273,000.00 | N/A |
| Revenue This Year | $36.03 | N/A |
| Revenue Next Year | $102.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 45.98 | N/A |
| 52 Week Low | $5.27 | $5.49 |
| 52 Week High | $16.49 | $36.51 |
| Indicator | ENVX | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 36.27 | 54.14 |
| Support Level | $5.69 | $31.00 |
| Resistance Level | $6.86 | $33.89 |
| Average True Range (ATR) | 0.48 | 1.96 |
| MACD | -0.06 | -0.28 |
| Stochastic Oscillator | 14.94 | 46.78 |
Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.